Prognostic factors and survival of ALS patients from Belgrade, Serbia

References

• Logroscino G., Traynor B, Hardiman O, Chio A, Couratier P, Mitchell JD, et al. Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues. J Neurol Neurosurg Psychiatry. 2008;79:6–11.
   PubMed Web of Science ®Google Scholar
• McDermott CJ, Shaw PJ. Diagnosis and management of motor neuron disease. Br Med J. 2008;336:658–62.
   PubMed Web of Science ®Google Scholar
• Hudson AJ. Amyotrophic lateral sclerosis and its association with dementia, Parkinsonism and other neurological disorders: a review. Brain. 1981;104:217–47.
   PubMed Web of Science ®Google Scholar
• Hardiman O, van den Berg LH, Kiernan MC. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol. 2011;7:639–49.
   PubMed Web of Science ®Google Scholar
• Preux P, Couratier P, Boutros-Toni F, Salle JY, Tabaraud F, Bernet-Bernady P, et al. Survival prediction in sporadic amyotrophic lateral sclerosis. Age and clinical form at onset are independent risk factors. Neuroepidemiology. 1996;15:153–60.
   PubMed Web of Science ®Google Scholar
• Traynor BJ, Codd MB, Forde C, Frost E, Hardiman OM. Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria. Arch Neurol. 2000;57:1171–6.
   PubMed Web of Science ®Google Scholar
• Armon C. Motor neuron disease. In: PB Gorelick, M Alter, editors. Handbook of Neuroepidemiology, New York: Marcel Dekker; 1994. pp 407–56.
   Google Scholar
• Chio A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, et al. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. 2009;10:310–23.
   PubMed Web of Science ®Google Scholar
• del Aguila MA, Longstreth WT Jr, McGuire V, Koepsell TD, van Belle G. Prognosis in amyotrophic lateral sclerosis: a population based study. Neurology. 2003;60:813–9.
   PubMed Web of Science ®Google Scholar
• Turner MR, Bakker M, Sham P, Shaw CE, Leigh PN, Al-Chalabi A. Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2002;3:15–21.
   PubMed Web of Science ®Google Scholar
• Magnus T, Beck M, Giess R, Puls I, Naumann M, Toyka KV. Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve. 2002;25:709–14.
   PubMed Web of Science ®Google Scholar
• Cronin S, Hardiman O, Traynor BJ. Ethnic variation in the incidence of ALS: a systematic review. Neurology. 2007;68:1002–7.
   PubMed Web of Science ®Google Scholar
• Drory V, Artmonov I. Earlier onset and shorter survival of amyotrophic lateral sclerosis in Jewish patients of North African origin – a clue to modifying genetic factors? Journal of the Neurological Sciences. 2007;258:39–43.
   PubMed Web of Science ®Google Scholar
• Brooks BR, Miller RG, Swash M, Munsat TL. World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293–9.
   PubMed Web of Science ®Google Scholar
• Alcaz S, Jarebinski M, Pekmezovic T, Stevic-Marinkovic Z, Pavlovic S, Apostolski S. Epidemiological and clinical characteristics of ALS in Belgrade, Yugoslavia. Acta Neurol Scand. 1996:94:264–8.
   PubMed Web of Science ®Google Scholar
• Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999;169:13.
   PubMed Web of Science ®Google Scholar
• Kaufmann P, Levy G, Thompson JL, Delbene ML, Battista V, Gordon PH, et al. The ALSFRS-R predicts survival time in an ALS clinic population. Neurology. 2005;64:38–43.
   PubMed Web of Science ®Google Scholar
• Logroscino G, Traynor BJ, Hardiman O, Chiò A, Mitchell D, Swingler RJ,. EURALS. Incidence of Amyotrophic Lateral Sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2010;81:385–90.
   PubMed Web of Science ®Google Scholar
• Beghi E, Logroscino G, Chiò A, Hardiman O, Mitchell D, Swingler R, EURALS Consortium. The epidemiology of ALS and the role of population based registries. Biochimica et Biophysica Acta. 2006;1762:1150–7.
   PubMed Web of Science ®Google Scholar
• Zaldivar T, Gutierrez J, Lara G, Carbonara M, Logroscino G, Hardiman O. Reduced frequency of ALS in an ethnically mixed population: a population based mortality study. Neurology. 2009:72:1640–5.
   PubMed Web of Science ®Google Scholar
• Horner RD, Kamins KG, Feussner JR, Grambow SC, Hoff-Lindquist J, Harati J, et al. Occurrence of amyotrophic lateral sclerosis among Gulf War veterans. Neurology. 2003;61:742–9.
   PubMed Web of Science ®Google Scholar
• Kasarskis EJ, Lindquist JH, Coffman CJ, Grambow SC, Feussner JR, Allen KD,. ALS Gulf War Clinical Review Team. Clinical aspects of ALS in Gulf War veterans. Amyotroph Lateral Scler. 2009;10:35–41.
   PubMed Web of Science ®Google Scholar
• Beard JD, Kamel F. Military service, deployments, and exposures in relation to amyotrophic lateral sclerosis aetiology and survival. Epidemiol Rev. 2015;37:55–70.
   PubMed Web of Science ®Google Scholar
• Danesi PR, Markowicz A, Chinea-Cano E, Burkart W, Salbu B, Donohue D, et al. Depleted uranium particles in selected Kosovo samples. Journal of Environmental Radioact. 2003;64:143–54.
   PubMed Web of Science ®Google Scholar
• Pugliatti M, Parish LD, Cossu P, Leoni S, Ticca A, Saddi MV, et al. Amyotrophic lateral sclerosis in Sardinia, insular Italy, 1995–2009. J Neurol. 2013;260:572–79.
   PubMed Web of Science ®Google Scholar
• Traynor BJ, Alexander M, Corr B, Frost E, Hardiman O. Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996–2000. J Neurol Neurosurg Psychiatry. 2003;74:1258–61.
   PubMed Web of Science ®Google Scholar
• Millul A, Berghi E, Logroscino G, Micheli A, Vitelli E, Zardi A. Survival of patients with amyotrophic lateral sclerosis in a population based registry. Neuroepidemiology. 2005;25:114–28.
   PubMed Web of Science ®Google Scholar
• Czaplinski A, Yen AA, Appel SH. Amyotrophic lateral sclerosis: early predictors of prolonged survival. J Neurol. 2006:253:1428–36.
   PubMed Web of Science ®Google Scholar
• Eisen A, Schulzer M, MacNeil M, Pant B, Mak E. Duration of amyotrophic lateral sclerosis is age dependent. Muscle Nerve. 1993;16:27–32.
   PubMed Web of Science ®Google Scholar
• Turner MR, Barnwell J, Al-Chalabi A, Eisen A. Young-onset amyotrophic lateral sclerosis: historical and other observations. Brain. 2012:135:2883–91.
   PubMed Web of Science ®Google Scholar
• Chio A, Traynor BJ, Lombardo F, Fimognari M, Calvo A, Ghiglione P, et al. Prevalence of SOD1 mutations in the Italian ALS population. Neurology. 2008;70:533–7.
   PubMed Web of Science ®Google Scholar
• Pupillo E, Messina P, Logroscino G, Ettore Beghi E and the SLALOM Group. Long-Term Survival in Amyotrophic Lateral Sclerosis: A Population-Based Study. Ann Neurol. 2014;75:287–97.
   PubMed Web of Science ®Google Scholar
• Haverkamp LJ, Appel V, Apple S. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain. 1995;118:707–9.
   PubMed Web of Science ®Google Scholar
• Lee JR, Annegers JF, Appel SH. Prognosis of amyotrophic lateral sclerosis and the effect of referral selection. J Neurol Sci. 1995:132:207–15.
   PubMed Web of Science ®Google Scholar
• Magnus T, Beck M, Giess R, Puls I, Naumann M, Toyka KV. Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve. 2002;25:709–14.
   PubMed Web of Science ®Google Scholar
• Forbes RB, Colville S, Cran GW, Swingler RJ. Unexpected decline in survival from amyotrophic lateral sclerosis/motor neuron disease J Neurol Neurosurg Psychiatry. 2004;75:1753–5.
   PubMed Web of Science ®Google Scholar
• Zoccolella S, Beghi E, Palagano G, Fraddosio A, Guerra V, Samarelli V,., SLAP Registry. Analysis of survival and prognostic factors in amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry. 2008:79:33–7.
   PubMed Web of Science ®Google Scholar
• Rauchway AC, Kaiboriboon K, Bansal SK, Kulkantrakorn K, Guo X, Parks BJ, et al. A role for functional classification in the early identification of prognostic factors in ALS. Amyotroph Lateral Scler. 2007;8:214–6.
   PubMed Web of Science ®Google Scholar
• Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994;330:585–91.
   PubMed Web of Science ®Google Scholar
• Paillisse C, Lacomblez L, Dib M, Bensimon S, Garcia-Acosta S, Meininger V. Prognostic factors for survival in amyotrophic lateral sclerosis patients treated with riluzole. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293–9.
   PubMed Web of Science ®Google Scholar
• Bensimon G, Lacomblez L, Delumeau JC, Bejuit R, Truffinet P, Meininger V, Riluzole/ALS Study Group II. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J Neurol. 2002;249:609–15.
   PubMed Web of Science ®Google Scholar
• Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2007;2:CD001447.
   Google Scholar
• Traynor BJ, Alexander M, Corr B, Frost E, Hardiman O. An outcome study of riluzole in amyotrophic lateral sclerosis. A population based study in Ireland, 1996–2000. J Neurol. 2003;250:473–9.
   PubMed Web of Science ®Google Scholar
• Mitchell JD, O’Brien MR, Joshi M. Audit of outcomes in motor neuron disease (MND) patients treated with riluzole. Amyotroph Lateral Scler Other Motor Neuron Disord. 2006;7:67–77.
   PubMed Web of Science ®Google Scholar